Project Scope
To understand the healthcare policies and potential access, reimbursement, funding opportunities for DLBCL CAR-T therapies in KSA
KSA
Challenge
Our client is a leading provider of targeted therapies for treatment of rare diseases. They wanted to understand the evolving healthcare policies, potential access and funding opportunities in private and public sector for CAR-T therapies in KSA
Solution
Conducted extensive primary research to get detailed insights on:
- Pricing and reimbursement process for high cost therapies in public and private sector
- National and hospital level and alternative funding pathways feasible for DLBCL CAR-T therapies
- Changes in healthcare policies in future impacting public funding for CAR-T in future
Results
- Enabled our client to understand local funding and access pathways for high cost therapies
- Recommended approaches from payer viewpoint to secure funding for high cost therapies in both private and public sector
Note: CAR-T: Chimeric antigen Receptor Therapies, DLBCL: Diffuse large B cell lymphoma, KSA: Kingdom of Saudi Arabia
